AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
1-Year Est. Return
29.75%
1 Year Est. Return
+29.75%
AUM
$639M
AUM Growth
-$1.35M
(-0.21%)
Holding
109
Top Buys
| 1 | +$16.8M | |
| 2 | +$15.6M | |
| 3 | +$13.1M | |
| 4 |
Nuvalent
NUVL
|
+$12.4M |
| 5 |
Mineralys Therapeutics
MLYS
|
+$11.9M |
Top Sells
| 1 | +$12.1M | |
| 2 | +$10.3M | |
| 3 | +$5.72M | |
| 4 |
Arrowhead Research
ARWR
|
+$5.64M |
| 5 |
Spyre Therapeutics
SYRE
|
+$5.53M |
Sector Composition
| 1 | Healthcare | 90.82% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.96B
| $44.6M | 4.25% |
1,328,175
+166,938
|
|
||
2
Apogee Therapeutics
APGE
$3.7B
| $43M | 4.1% |
1,151,199
+219,471
|
|
||
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $39M | 3.73% |
615,000
-45,000
|
|
||
4
Arcellx
ACLX
$5B
| $34.8M | 3.32% |
530,000
+105,000
|
|
||
5
Alkermes
ALKS
$5.43B
| $33M | 3.15% |
1,000,000
-100,000
|
|
||
|
6
Nuvalent
NUVL
$6.79B
| $32.6M | 3.11% |
460,000
+175,000
|
|
||
7
Madrigal Pharmaceuticals
MDGL
$11.1B
| $26.5M | 2.53% |
80,000
-2,500
|
|
||
|
CNTA
8
Centessa Pharmaceuticals
CNTA
$2.97B
| $22.2M | 2.12% |
1,546,662
+450,738
|
|
||
9
Teva Pharmaceuticals
TEVA
$27.5B
| $21.5M | 2.05% |
1,400,000
|
|
||
10
Protagonist Therapeutics
PTGX
$4.97B
| $19.3M | 1.85% |
400,000
+270,000
|
|
||
11
Travere Therapeutics
TVTX
$2.89B
| $19.2M | 1.83% |
1,070,000
+870,000
|
|
||
|
12
Mineralys Therapeutics
MLYS
$2.95B
| $17.5M | 1.67% |
1,100,000
+750,000
|
|
||
13
SPDR S&P 500 ETF Trust
SPY
$666B
| $16.8M | 1.6% |
+30,000
|
|
||
14
Wave Life Sciences
WVE
$1.25B
| $14.7M | 1.41% |
1,825,000
+325,000
|
|
||
15
Merus
MRUS
$7.22B
| $13.6M | 1.29% |
321,962
-67,279
|
|
||
16
Axsome Therapeutics
AXSM
$6.96B
| $11.7M | 1.11% |
100,000
+25,000
|
|
||
17
Establishment Labs
ESTA
$1.88B
| $11.4M | 1.09% |
280,000
+555
|
|
||
18
Insmed
INSM
$40.5B
| $10.7M | 1.02% |
140,000
+90,000
|
|
||
19
BridgeBio Pharma
BBIO
$11.9B
| $10.4M | 0.99% |
300,000
+100,000
|
|
||
20
Nurix Therapeutics
NRIX
$1.25B
| $9.63M | 0.92% |
810,669
-129,414
|
|
||
21
Vera Therapeutics
VERA
$1.55B
| $8.53M | 0.81% |
355,143
-69,857
|
|
||
22
Trevi Therapeutics
TRVI
$1.34B
| $7.86M | 0.75% |
+1,250,000
|
|
||
|
23
Spyre Therapeutics
SYRE
$1.75B
| $7.77M | 0.74% |
481,678
-342,650
|
|
||
24
Immunovant
IMVT
$4.07B
| $7.35M | 0.7% |
430,000
+330,000
|
|
||
25
NewAmsterdam Pharma
NAMS
$4.17B
| $6.65M | 0.63% |
325,000
-100,000
|
|